Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for global professionals · Wednesday, September 23, 2020 · 526,904,123 Articles · 3+ Million Readers

Angiotech Pharmaceuticals Files $250 Million Mixed Shelf

July 24, 2009 (FinancialWire) — Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI) has filed a preliminary short form base shelf prospectus with the securities commissions of British Columbia and Ontario and a corresponding shelf registration statement with the U.S. Securities and Exchange Commission to allow Angiotech to offer up to $250 million during the next 25 months.

The offerings may consist of common shares, class I preference shares, debt securities, warrants or units and will be made to potential purchasers in British Columbia, Ontario and the United States.

Angiotech plans to use the proceeds from any such offering for general corporate purposes, including funding research and development programs, capital expenditures, working capital and/or repayment or refinancing of the company’s outstanding indebtedness.

Vancouver-based Angiotech Pharmaceuticals is a specialty pharmaceutical and medical device company with over 1,500 dedicated employees.

Angiotech discovers, develops and markets treatment solutions for diseases or complications associated with medical device implants, surgical interventions and acute injury.

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site ( Contact FinancialWire(tm) directly via

Free annual reports for companies mentioned in the news are available through the Free Annual Reports Service (

Powered by EIN Presswire

EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release